Ankur Dhingra

Ankur Dhingra

Former Chief Financial OfficeratSummit Therapeutics· In proxies 2022–2024

Pay in FY2024Summit Therapeutics stock +583.7% the same year

Ankur Dhingra was paid $256.3K in FY2024 (Dec). Summit Therapeutics stock rose 583.7% that year.

Pay$100 in the stock at the end of FY23 → $684
Pay is from the Summary Compensation Table of each Summit Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Summit TherapeuticsPublic company · 4 yr
    • Former Chief Financial Officer2022 – Present · 4 yrStock in role +484%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?